Recent studies have shown that in vitro inhibition of Jak1 and Jak2 with ruxolitinib reduced the proliferation and migration of PASMCs in patients with PAH in a dose-dependent manner [29]. The gene discussed is JAK1; the disease is pulmonary arterial hypertension.